A Longitudinally Stable Anti-coactivation Pattern Between the Cerebellum and the Ventral Tegmental Area Relates to Apathy in Schizophrenia

Authors
Farnaz Delavari1,2*, Jade Awada3*, Dimitri Van De Ville4,5, Thomas A. W. Bolton3, Mariia Kaliuzhna6, Fabien Carruzzo6, Noemie Kuenzi6, Florian Schlagenhauf7, Fares Alouf3, Stephan Eliez1, Stefan Kaiser6,8, Indrit Bègue3,8

Affiliations
1. Developmental Imaging and Psychopathology Laboratory, University of Geneva School of Medicine, Geneva, Switzerland
2. Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Switzerland
3. Neuroimaging and translational psychiatry lab, Department of psychiatry, University of Geneva, Switzerland
4. Institute of Bioengineering, Ecole Polytechnique de Fédérale de Lausanne (EPFL), Lausanne, Switzerland
5. Department of radiology and medical informatics, University of Geneva, Switzerland
6. Laboratory for experimental psychopathology, Department of psychiatry, University of Geneva, Switzerland
7. Department of Psychiatry and Neurosciences, Campus Charité Mitte, Berlin, Germany
8. Adult psychiatry division, Department of psychiatry, University Hospitals of Geneva, Switzerland

*Shared authorship

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Corresponding author
Indrit Bègue, indrit.begue@unige.ch
Laboratory for neuroimaging and translational psychiatry,
Department of psychiatry, University of Geneva, Switzerland
Campus Biotech, Chemin des Mines 9, 1202, Geneva Switzerland
Abstract

Background
Negative symptoms in schizophrenia are debilitating and lack effective treatments. Reward system dysfunction and cerebellum anomalies have been linked to negative symptoms. Evidence suggests the cerebellum modulates the reward system via the ventral tegmental area (VTA). The "cognitive dysmetria theory" posits that reduced cerebellar inhibition in schizophrenia may underlie striatal hyperdopaminergia. However, cerebellum-VTA connectivity and its impact on negative symptoms in schizophrenia remains unclear.

Method
In a longitudinal study, we conducted interviews and acquired resting-state functional magnetic resonance imaging (rs-fMRI) in 146 individuals, including patients with schizophrenia (SZ) and healthy controls (HC). The Brief Negative Symptom Scale (BNSS) was used to quantify negative symptoms. After quality check, the final sample included 105 individuals (58 SZ) at baseline (T1), 41 individuals (22 SZ) at 3-month follow-up (T2), and 21 patients at 9-month follow-up (T3; interviews only). We analyzed the dynamic functional connectivity of cerebellum and VTA activity using Co-Activation Patterns (CAPs) analysis.

Results
We identified a longitudinally stable anti-coactivation cerebellum-VTA pattern across baseline and T2 (rho = 0.98) encompassing bilateral paravermal regions of Crus I and II. Across all timepoints, the anti-coactivation spatial pattern's persistence quantified by its duration, was significantly reduced in schizophrenia, indicating an enduring deficiency in cerebellar inhibition of the VTA. Lower emergence of this pattern at T1 and lower persistence at T2 were associated with more severe apathy but not diminished expression. Further, lower persistence at T2 predicted more severe apathy but not diminished expression 6 months later.

Conclusion
These results provide stable longitudinal evidence on the cerebellum's "dysmetric" regulatory effect on reward circuitry in schizophrenia and open the perspective for targeted cerebellar non-invasive brain stimulation to alleviate negative symptoms.
INTRODUCTION

Negative symptoms in schizophrenia – a chronic psychiatric condition affecting up to 1% of the population – are marked by features such as apathy (asociality, anhedonia and avolition) or diminished expression (blunted affect, alogia) (1). Negative symptoms represent a key unmet need in psychiatry due to their profound effect on social functioning, their prevalence across various stages of the disorder and antipsychotic medication resistance (1). Therefore, a better understanding of the underlying mechanisms and pathways involved in negative symptoms in schizophrenia is crucial for advancing treatment options.

Recent conceptualizations of negative symptoms have evolved to map these symptoms onto two dimensions: apathy (avolition, anhedonia, asociality) manifesting as reductions in goal directed behavior, pleasure and social communication and diminished expression in the emotional and verbal domain (blunted affect and alogia) (2). Emerging evidence highlights a link between negative symptoms, in particular, apathy to dysfunctions in the reward system including the Ventral Tegmental Area (VTA; mesolimbic pathway) (3,4). Parallel to these findings, the cerebellum, traditionally recognized for its role in motor coordination has been increasingly implicated in reward processing (5) and the pathophysiology of negative symptoms in schizophrenia (4,6). From early neuroimaging to modern day research, cerebellar vermis structural reduction (7) and altered cerebellar-cortical functional connectivity (8–10) have pointed to a key role of the cerebellum in schizophrenia.

A seminal theory on cerebellar involvement in schizophrenia was conceptualized with the Cognitive Dysmetria Theory (11), given links between forebrain hyperdopaminergia and cerebellar vermis malfunction from reductions in Purkinje cell size and density in post-mortem studies (12). This theory postulated that malfunction of the cerebellar cortex would lead to disinhibition of excitatory projections from the deep nuclei to dopaminergic neurons in the midbrain, resulting in a "hyperdopaminergic state" (13). Consistent with this hypothesis, Daskalakis et al. (2005) examined cerebellar brain inhibition in patients with schizophrenia and found an almost 30% reduction compared to healthy controls (14). Cerebellar brain inhibition refers to the inhibitory tone exerted by the cerebellum on motor neural circuits manifested as a reduction in motor evoked...
potential when the cerebellum is stimulated 5-7 ms prior to the motor cortex (15). These findings raise the possibility that the cerebellum may be implicated in the negative symptoms pathophysiology via the exertion of modulatory role on the reward system (16), analogous to its established role on motor control. This hypothesis is grounded in several mechanistic insights tying the cerebellum to reward circuitry: 1) activity within the cerebellum during reward anticipation has been consistently observed in human neuroimaging (17) and rodent studies (18); 2) direct monosynaptic connections from the deep cerebellar nuclei to the VTA have been documented in both animal (19–21) and human studies (22–24); 3) the cerebellum exerts an inhibitory tone on the Papez circuit (23) and its stimulation was found to be associated to ‘pleasure’ and stopping of seizure starting from the hippocampus (24). In addition, the cerebellum's contribution to the negative symptoms pathophysiology, especially through its effects on the reward system, can be understood by considering its intrinsic role in coordinating and timing of neural processes (5). Thus, in sum, the cerebellum's capacity to integrate inputs relevant to reward processing and modulate reward-related activities through precise timing and coordination, could underlie the mechanisms behind cerebellar contributions to the negative symptom pathophysiology.

A key role for the cerebellum with high therapeutic potential to address negative symptoms is further supported from recent non-invasive cerebellar neuromodulation evidence, convergently indicating improvement in the negative symptoms severity (25). Cerebellar transcranial magnetic stimulation (TMS) active stimulation but not sham increased resting-state functional connectivity between the vermian-pallidal areas (26), suggesting a functional linkage with regions in the reward circuitry. Overall, this evidence suggests that the cerebellum's connectivity with the reward system, especially its interactions with the VTA, should provide clinically relevant insights. However, the functional connectivity between the cerebellum and the VTA in the context of negative symptoms remains largely unknown and has not been examined in schizophrenia.

In this research, we set out to investigate for the first time the connectivity between the cerebellum and the VTA and its longitudinal trajectory across three time points (baseline, at 3- and 9 months) in a well-characterized cohort of patients with schizophrenia. We leveraged the Co-Activation Patterns toolbox (27), an analytical
method designed to capture transient neural coactivation events between brain regions during resting state. We focused on the VTA as the seed region and observed its interaction with spatial patterns of coactivity within the cerebellum identified through coactivation maps - CAP. We subsequently derived metrics related to these spatial patterns: emergence (i.e., CAP entry frequency, quantifying the number of times a certain pattern of coactivation occurred from VTA inactivity) and persistence (i.e., CAP duration quantifying the time in seconds a certain pattern of coactivation persisted upon occurring). We hypothesized that the functional connectivity patterns between the VTA and the cerebellum during resting state and their associated metrics (emergence and persistence) were linked to schizophrenia clinical manifestations and would represent a stable functional signature of negative symptoms in schizophrenia over time.

METHODS

Data Collection and Participant Characteristics
We systematically collected demographic, clinical, cognitive, behavioral, and neuroimaging data. The total cohort included 146 individuals (90 patients with schizophrenia spectrum disorder (SZ) and 56 healthy controls (HC) at baseline, 65 individuals (36 SZ and 29 HC) 3 months later (T2), and 33 SZ 9 months after baseline (T3). Participants were administered a series of interviews and neuroimaging protocols at baseline and 3 months follow-up (T2) and only interviews at 9 months follow-up (T3). The cohort was recruited in the context of two studies approved by the Geneva Ethics Committee in Switzerland (CCER. BASEC ID: 2017-01765 and 2020-02169).

Here, we included clinically stable patients with schizophrenia with no changes in medication and no hospitalizations in the last 3 months from community out-patient centers in the University Hospital of Geneva, Switzerland (Figure 1A). Patients had confirmed schizophrenia diagnosis via the Mini International Neuropsychiatric Interview (28). To exclude secondary sources of negative symptoms (e.g., psychosis, extrapyramidal effects, medication, social deprivation), patients were not included if they presented other axis-I disorders, in particular, characterized major depressive episodes, florid psychotic symptoms (Positive and Negative Syndrome Scale, any
positive item > 4 (29), significant extrapyramidal side-effect (any St Hans Rating scale (30) item > 3), use of benzodiazepines of more than 1mg/of lorazepam equivalents, or active use of substances (including opiate substitution for medical purposes). Healthy controls were included only if they did not present any axis-I disorder, a family history of psychotic disorders or psychotropic drug use.

Clinical psychopathological and cognitive assessment
All individuals (HC and SZ) underwent a detailed psychopathological assessment. To assess the negative symptoms in patients with schizophrenia, we used the Brief Negative Symptoms Scale (BNSS) (1), a semi-structured interview conducted by trained researchers/clinicians. The BNSS is a second-generation instrument based on the NIMH-MATRIC consensus statement that is now widely recommended (2). 32 patients and 9 controls at T1 and 14 patients and 10 controls at T2 during different stages of quality control of the imaging analysis. The reasons for exclusion are detailed in a flowchart in the Supplemental Materials. Out of 33 patients who returned for interviews at T3, only 21 subjects had scans in T2. Thus, the final sample consisted of 105 individuals (58 SZ and 47 HC) at T1, 41 individuals (22 SZ and 19 HC) at T2, and 21 SZ at T3.

Dynamic resting state functional connectivity analysis
To examine the cerebellum-VTA co-activation patterns, we employed the publicly available tbCAPs toolbox (27) (Figure 1B). In brief, time-points with pronounced VTA activity are identified. Then, cerebellar activity at the same timepoints is retained and clustered into a set of spatial patterns expressed on these timepoints. These patterns indicate functionally relevant networks within the cerebellum during the VTA activation. We employed the left and right VTA masks of the Automated Anatomical Labeling (AAN) (31) atlas as basis for these analyses. We followed the standard procedure for CAP analysis in which, for each rs-fMRI session, the BOLD signal time-series from voxels within the bilateral VTA were extracted, averaged, and standardized (Z-scored). We selected time points with an average time-course value exceeding 1 (arbitrary scaling) and with frame-wise displacement lower than 0.5 mm (scrubbing), consistent with established literature (32). K-means clustering was employed to group these selected volumes, derived from both patient and control groups into distinct spatial clusters. In this study, we focused on the cerebellum for clustering analyses. Cluster
stability was validated through a train-and-test approach, which is described in the Supplemental Materials. This approach resulted in four CAPs that were visualized using cerebellar flatmaps (33). The CAPs voxel values were subsequently converted to T-values, using the formula:

\[ t = \frac{x}{s} \sqrt{\frac{1}{n}} \]

where \( x \) is the average of BOLD values for the voxel within the frames for a selected for a CAP, \( s \) is the value’s standard deviation, and \( n \) is the number of frames assigned to that CAP. These maps effectively quantify the extent and stability of voxel activity within each dynamic state.

To examine the longitudinal stability of CAPs across all follow-up time-points, we analyzed the similarities between spatial patterns at T1 and T2. Therefore, we calculated Pearson correlations between all pairs of CAPs between T1 and T2, respectively, and arranged them into a correlation matrix.

**Group comparison and associations of CAP metrics with negative symptoms**

CAP metrics were calculated as described in the toolbox publication (27) (Figure 1B). Briefly, for each CAP, we calculated persistence i.e., the average time, in seconds, a CAP persisted consecutively upon occurrence. Moreover, we measured the emergence, denoting the frequency, irrespective of duration by which a specific CAP occurred after VTA under-threshold activity.

Statistical analyses included non-parametric testing with rank tests for median comparisons and Spearman’s correlation for examining associations with psychopathology assessments, conducted in Python 3.9 using statsmodels 0.14.1 (Figure 1C). To account for movement in the scanner and medication intake, framewise displacement and risperidone equivalent dose were included as variables in group comparisons of CAP metrics and partial correlation analyses with psychopathology. Within the patient cohort, we assessed the psychopathological relevance of our findings by examining associations between the metrics of cerebellar CAP of interest (emergence, persistence) and the severity of negative symptoms (apathy and diminished expression) as measured by BNSS. The False Discovery Rate (FDR) was controlled using the Benjamini-Hochberg procedure to adjust p-values for multiple
comparisons. All reported significant results survive FDR correction at a significant level of p<0.05 unless reported otherwise. The code for behavioral data analyses can be found at: [https://drive.google.com/drive/folders/1roAKf33fQ1S_q0uajCnlcPQv1V8-Th6t?usp=drive_link](https://drive.google.com/drive/folders/1roAKf33fQ1S_q0uajCnlcPQv1V8-Th6t?usp=drive_link)

Figure 1. Study design, Co-Activation Pattern (CAP) analysis and statistical pipeline overview. A. Study design. Healthy controls (HC) and patients (SZ) underwent an MRI scan and detailed psychopathological assessment at baseline (T1) and at 3 months follow-up (T2). At 9 months after baseline (T3), only patients were invited and assessed with psychopathological testing alone. B. Resting state analysis. B.1-2. Average VTA signal (seed) for each individual is standardized and thresholded at 1 and time-points exceeding this threshold (red circles) are selected denoting time-points with VTA co-activity. We then performed a K-means clustering on the cerebral voxels at these time-points to obtain cerebral patterns. B.3. Within each individual, for each CAP, persistence is calculated as the average time in seconds a CAP lasts after occurring. Cap emergence is measured, as the number of times a specific CAP occurred after the VTA under-threshold activity. C. Statistical analyses pipelines. Group comparison for CAP metrics between HC and SZ and the clinical relevance for patients is assessed with associations between CAP metrics and negative symptoms.
RESULTS

Demographic, neuroimaging, and clinical data

A summary of the cohort characteristics across timepoints can be found in Table 1. The patient population was matched for age and sex to healthy controls and included chronic and clinically stable patients with low levels of psychosis, depression and extrapyramidal syndrome. Negative symptoms in the patients’ cohort were enduring across time-points and were not associated with psychosis, medication, cognitive dysfunction, or extrapyramidal effects, suggesting that these symptoms were unconfounded by other clinical factors (see Supplemental Materials).
Table 1. Demographic and Psychopathology Characteristics of Study Participants

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Baseline (T1)</th>
<th>3 months from T1 (T2)</th>
<th>9 months from T1 (T3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group</td>
<td>SZ (N=58)</td>
<td>HC (N=47)</td>
<td>SZ (N=22)</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Age</td>
<td>36.138</td>
<td>9.391</td>
<td>38.745</td>
</tr>
<tr>
<td>Sex (Percentage of males)</td>
<td>84.5%</td>
<td>70.2%</td>
<td>0.128 (Chi-square test)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neuroimaging</th>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th>p</th>
<th>Mean</th>
<th>SD</th>
<th>Mean</th>
<th>SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean of Frame-wise displacement during resting state fMRI</td>
<td>0.262</td>
<td>0.104</td>
<td>0.200</td>
<td>0.088</td>
<td>0.002 (two sample t-test)</td>
<td>0.276</td>
<td>0.113</td>
<td>0.197</td>
<td>0.091</td>
<td>0.020 (two sample t-test)</td>
</tr>
<tr>
<td>#</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical and psychopathology information</th>
<th>Group</th>
<th>Baseline (T1) (N=58)</th>
<th>3 months from T1 (T2) (N=22)</th>
<th>9 months from T1 (T3) (N=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative symptoms</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>BNSS diminished expression</td>
<td>6.655</td>
<td>7.097</td>
<td>7.000</td>
<td>7.051</td>
</tr>
<tr>
<td>BNSS apathy</td>
<td>12.466</td>
<td>8.672</td>
<td>11.409</td>
<td>9.231</td>
</tr>
<tr>
<td>Psychosis</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>PANSS psychosis</td>
<td>9.603</td>
<td>2.655</td>
<td>9.182</td>
<td>2.612</td>
</tr>
<tr>
<td>Depression</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>CDS</td>
<td>2.190</td>
<td>3.080</td>
<td>2.318</td>
<td>3.168</td>
</tr>
<tr>
<td>Cognition</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>BACS</td>
<td>35.672</td>
<td>10.743</td>
<td>33.955</td>
<td>13.185</td>
</tr>
</tbody>
</table>

*CC-BY 4.0 International license*
<table>
<thead>
<tr>
<th>Psychosocial functioning</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PSP</td>
<td>4.397</td>
<td>1.736</td>
<td>5.091</td>
<td>1.444</td>
<td>5.095</td>
<td>1.758</td>
</tr>
<tr>
<td><strong>Antipsychotic medication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose in risperidone equivalent</td>
<td>4.509</td>
<td>2.629</td>
<td>4.420</td>
<td>2.407</td>
<td>4.652</td>
<td>2.814</td>
</tr>
<tr>
<td><strong>Extrapyramidal syndrome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SHRS</td>
<td>1.017</td>
<td>0.827</td>
<td>1.136</td>
<td>1.246</td>
<td>1.143</td>
<td>1.195</td>
</tr>
<tr>
<td><strong>Measure of illness chronicity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of hospitalizations in the last 6 months*</td>
<td>0.075</td>
<td>0.267</td>
<td>#</td>
<td></td>
<td>#</td>
<td></td>
</tr>
<tr>
<td>Duration of Illness (Years) **</td>
<td>12.038</td>
<td>7.488</td>
<td>#</td>
<td></td>
<td>#</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BNSS = Brief Negative Symptoms Score; PANSS = Positive and Negative Symptom Scale; CDS = Calgary Depression Scale for Schizophrenia; PSP = Personal and Social Performance Scale; BACS = Brief Assessment of Cognition in Schizophrenia; SHRS = St. Hans Rating Scale; healthy controls (HC); schizophrenia (SZ).

*Data not available for 2 patients.
**Data not available for 6 patients.
# Data not available.
Baseline investigation of the cerebellar temporal coupling with the VTA

Baseline co-activation patterns of cerebellum with the VTA

Our neuroimaging analysis uncovered four spatially distinct cerebellum - VTA co-activation patterns (CAPs; Figure 2A, refer to the Supplemental Materials for the selection of optimal number of clusters). CAP1 was identified as cerebellar anti-coactivation with the VTA and was strongest at bilateral paravermal regions of Crus I and II. CAP2 showed VTA coactivation within lobule VI extending to Crus I and II. CAP3 encompassed with mainly anterior lobe (lobules I-V), as well as posterior lobe (lobules VIIA and VIIIB). Finally, CAP4 showed a pattern of VTA anti-coactivation predominantly within lateral Crus I and lobule VI.
Figure 2. Spatial patterns of co-activity between the cerebellum and the VTA in patients (SZ) and controls (HC) and their relation to negative symptoms at baseline. A. Distinct spatial maps of the cerebellum coactivation with the VTA. B. Reduced anti-coactivation persistence (duration in seconds of CAP1) in patients with schizophrenia compared to HC. C. Reduced anti-coactivation emergence (CAP 1 entry frequency) is associated with greater severity of apathy (in green) but not diminished expression (in grey). Note. Negative symptoms quantified by Brief Negative Symptom Scale (BNSS). Greater scores indicate more severe symptoms. Dim.exp = diminished expression. The colorbar represents T-values. Group comparisons and correlations are corrected for movement (framewise displacement) and antipsychotic medication (risperidone equivalent).
Baseline anti-coactivation pattern persistence is reduced in schizophrenia and its emergence relates to apathy but not diminished expression

We compared each CAP's persistence (average duration in seconds of a CAP) and emergence (number of times a specific CAP emerges after the VTA under-threshold activity) between patients with schizophrenia and HC and found a significantly shorter CAP1 in patients (F Statistic = 16.13, p = 0.0009) (Figure 2B). Correction for antipsychotic dosage in patients (quantified by risperidone equivalents) did not affect this result (F Statistic = 5.609, p = 0.020). We found no significant differences in the persistence of the remaining three CAPs across the two diagnostic groups. Further, we found no significant differences in CAP emergence between the groups.

Therefore, we focused on the clinical relevance of the anti-coactivation pattern for patients, by assessing the association between negative symptoms (apathy and diminished expression quantified by the BNSS subscales) and CAP1 metrics (emergence, persistence) given its shorter duration in schizophrenia. We found that CAP1 persistence was not associated to apathy or diminished expression. However, CAP1 emergence was significantly negatively correlated with the severity of apathy ($\rho = -0.31$, p = 0.035). The association with the severity of diminished expression was not significant ($\rho = -0.25$, p = 0.099) (Figure 2C). Correction for antipsychotic dosage (quantified by risperidone equivalents) yielded similar results (apathy: $\rho = -0.34$, p = 0.023; diminished expression: $\rho = -0.25$, p = 0.097).

Investigation of cerebellar temporal coupling with the VTA at 3-month follow-up

Longitudinally stable co-activation patterns of cerebellum with the VTA

Similar to baseline, we identified four distinct cerebellum-VTA CAPs at 3-month follow-up (T2; Figure 3A). Comparison of spatial similarity at baseline and T2 using pairwise spatial correlation showed that anti-coactivation patterns at both timepoints were spatially almost identical ($\rho = 0.981$, p < 0.001), indicating a stable functional signature over time (Figure 3B).
Figure 3. Spatial patterns of co-activity between the cerebellum and the VTA in patients (SZ) and controls (HC) and their relation to negative symptoms at 3-month follow-up. A. Distinct spatial maps of the cerebellum co-activation with the VTA. B. Correlation matrix between CAPs at T1 and CAPs at T2. C. Reduced anti-coactivation persistence (duration in seconds of CAP1) in patients with schizophrenia compared to HC. D. Reduced anti-coactivation persistence is associated with greater severity of apathy (in green) but not diminished expression (in grey).

Note. Negative symptoms are quantified by Brief Negative Symptom Scale (BNSS). Greater scores indicate more severe symptoms. Dim.exp = diminished expression. The colorbar represents T-values. Group comparisons and correlations are corrected for movement (framewise displacement) and antipsychotic medication (risperidone equivalent).

Anti-coactivation pattern persistence is reduced in schizophrenia and relates to apathy but not diminished expression at 3-month follow-up

We examined the anti-coactivation pattern persistence and emergence between patients with schizophrenia and HC, and similar to baseline, found a significantly
shorter anti-coactivation (CAP1) duration in patients at 3-month follow-up (F Statistic = 6.970, p = 0.026; correction for framewise displacement and antipsychotic medication) (Figure 3C).

Anti-coactivation pattern persistence was significantly negatively correlated with the severity of apathy (\( \rho = -0.57, \ p = 0.023 \)) but not of diminished expression (\( \rho = -0.01, \ p = 0.968 \)) (Figure 3D; Spearman correlations corrected for framewise displacement and antipsychotic medication). By contrast, CAP1 emergence did not relate to negative symptom severity.

**Anti-coactivation persistence at 3-month follow-up is associated with apathy at 6-month follow-up**

Finally, we asked whether CAP1 persistence at baseline or at 3-month follow-up (T2) could be linked to symptoms at the 9-month follow-up (T3). We found that CAP1 metrics at baseline were not associated with apathy or diminished expression at T3. By contrast, the persistence of the anti-coactivation pattern at 3-month follow-up was negatively correlated to the severity of apathy at 9-month follow-up (\( \rho = -0.48, \ p = 0.049 \)), but not of diminished expression (\( \rho = -0.20, \ p = 0.412 \)) (Figure 4; Spearman correlations corrected for framewise displacement and antipsychotic medication).

![Figure 4. Relation of CAP 1 persistence at 3-month follow-up to negative symptoms at 9-month follow-up.](image)

Reduced anti-coactivation persistence (CAP 1 duration in seconds) is associated with greater severity of apathy (in green) but not diminished expression (in grey).
Note. Negative symptoms are quantified by Brief Negative Symptom Scale (BNSS). Greater scores indicate more severe symptoms. Dim.exp = diminished expression. Correlations are corrected for movement (framewise displacement) and antipsychotic medication (risperidone equivalent).
DISCUSSION

We uncovered a longitudinally stable spatial functional signature of anti-coactivation involving the cerebellar vermis and paravermis regions within Crus I – Crus II and the VTA in schizophrenia. This pattern was replicated into two distinct recordings (i.e., at baseline and at 3-month follow-up) with very high concordance (Figure 3B). In both recordings, we observed a diminished persistence (i.e., average duration) of this anti-coactivation pattern in patients with schizophrenia, possibly suggesting an enduring deficiency in the cerebellar gatekeeping of the VTA. Patients with scarcer emergence and reduced persistence of anti-coactivation had more severe apathy, but not diminished expression, suggesting that this pattern may be important for motivated behavior.

Our findings concord with evidence of a dysfunctional cerebellar ‘inhibitory tone’ over deeper structures (15,20) that could contribute to the excitatory/inhibitory (E/I) imbalance observed in schizophrenia (34). The balance between neuronal excitation and inhibition is crucial for optimizing the signal-to-noise ratio within neuronal networks (35). Dysregulation of cerebellar neurons projecting to midbrain would disrupt the E/I and the signal-to-noise ratio, thereby diminishing the brain’s ability to distinguish between rewarding and non-rewarding stimuli leading to apathy (34). Given its anatomical structure with excitatory (i.e., granule cells) and inhibitory neurons (i.e., Purkinje cells), the cerebellum is a central hub for regulating both inhibition and excitation. The cerebellar Purkinje cells that coordinate the glutamatergic cerebellar output, have very high metabolic energy demands which makes them susceptible to damage (36) and thus prone to disturbing the E/I balance upon exposure to genetic and environmental stressors. Post-mortem studies of individuals with autism – a disorder also presenting with amotivated behavior and clinical overlap with schizophrenia - corroborated a reduced number of Purkinje cells, as well as alterations in cerebellum’s volume and connectivity (37). In sum, the cerebellum’s critical role in gatekeeping neuronal excitation and inhibition, coupled with its vulnerability to genetic and environmental stressors points to its key role in the pathophysiology of amotivated behavior across schizophrenia and other developmental disorders.
In our study, we observed that the persistence of the anti-coactivation pattern expressed in the medial (i.e., CAP 1) but not the lateral cerebellum (i.e., CAP 4) related to apathy over time (T2, T3). The implication of medial cerebellum in the paravermis area provides further support for the Cognitive Dysmetria theory that postulated a key role of these regions in schizophrenia (38). The vermis and paravermis regions of Crus I and II, unlike their lateral counterparts, have unique molecular properties that may confer resilience to stress, enabling compensatory processes that require time in line with our findings (Figure 4). Specifically, Purkinje cells in these posterior cerebellar areas express zebrin-II, a highly conserved across-vertebrates protein, that provides resistance to injury (39), unlike the motor cerebellum, which is zebrin-II negative and more susceptible to stress. Accordingly, this would imply developmental stress to impact the motor cerebellum before non-motor areas. In this context, schizophrenia's clinical presentation could be viewed through cerebellar zebrin patterns, with initial "soft" neurological dysfunctions such as ataxia and dysmetria relying on motor areas (40) preceding negative and cognitive symptoms relying on posterior cerebellum. Investigating the molecular mechanisms in these regions could enhance our understanding of dysfunctional cerebellar circuits in schizophrenia and should be the focus of future efforts (4,16).

Our study not only sheds light on the cerebellum regulatory role in the pathophysiology of apathy in schizophrenia but also opens new avenues for therapeutic intervention. The specific cerebellar-VTA connectivity patterns we identified offer promising targets for anti-coactivation guided individualized cerebellar transcranial magnetic stimulation (TMS), aiming to restore functional neural circuits and alleviate negative symptoms in schizophrenia.

Our study has strengths and limitations. We identify for the first time a longitudinally stable anti-coactivation pattern of the cerebellum–VTA connectivity in humans, bridging a critical gap on how the cerebellum regulates the reward circuitry over time. We used a clinical cohort with negative symptoms and minimal confounding impact from psychosis, medication or extrapyramidal effects. Furthermore, we used a scale specifically designed to measure negative symptoms excluding items related to non-negative symptom psychopathology domains included in older scales (1,16). Regarding limitations, as with all resting state neuroimaging, our measure of cerebellar
activity is indirect. However, BOLD activity has been linked to excitatory function (32), therefore the observed anti-coactivation likely indicates either increased inhibition or reduced excitatory activity. To reflect this nuance, in this research we have employed the term "anti-coactivation" to remain agnostic about the underlying (i.e., inhibitory) mechanism. However, future studies should aim to directly examine the specific neuronal activity and mechanisms underlying these patterns to provide a clearer understanding. In humans, this could be achieved through advanced imaging techniques like magnetoencephalography or invasive electrophysiological recordings in specific neurosurgical contexts, along with non-invasive neuromodulation techniques like TMS to infer underlying mechanisms.

In conclusion, we identified a longitudinally stable anti-coactivation pattern of cerebellum-VTA to relate to apathy in schizophrenia. These results open new avenues for therapeutic interventions through resting-state anti-coactivation targeted cerebellar neuromodulation for more effective and personalized treatments.
**Funding**: Leenaards Foundation grant awarded to IB. Swiss National Science Foundation Grant No 169783 to SK.

**Contributions**: Farnaz Delavari: Investigation, Methodology, Formal analysis, Writing original draft, Visualization. Jade Awada: Investigation, Formal analysis, Writing original draft, Visualization. Dimitri Van De Ville: Methodology, Review and editing of manuscript. Thomas A. Bolton: Methodology, Review and editing of manuscript. Mariia Kaliuzhna: Data acquisition. Fabien Carruzzo: Data acquisition. Noemie Kuenzi: Data acquisition. Florian Schlagenhauf: Data acquisition. Fares Alouf: Data acquisition. Stephan Eliez: Review and editing of manuscript. Stefan Kaiser: Resources, Review and editing of manuscript. Indrit Bègeue: Conceptualization, Investigation, Resources, Supervision, Project administration, Funding acquisition, Writing original manuscript.

Farnaz Delavari and Jade Awada contributed equally to this article.

**Conflicts of interest**: SK has received advisory board honoraria from Boehringer Ingelheim and Exeltis. The other authors report no conflicts of interests.
References